Clinuvel Pharmaceuticals Limited (ASX:CUV)’s share price reached a new 52-week high during trading on Sunday . The stock traded as high as A$35.77 ($25.37) and last traded at A$35.77 ($25.37), with a volume of 144938 shares changing hands. The stock had previously closed at A$35.77 ($25.37).

The company has a market cap of $1.75 billion and a P/E ratio of 109.72.

COPYRIGHT VIOLATION NOTICE: “Clinuvel Pharmaceuticals (ASX:CUV) Sets New 52-Week High at $35.77” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at

About Clinuvel Pharmaceuticals (ASX:CUV)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe.

See Also: Why Invest in Dividend Achievers?

Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with's FREE daily email newsletter.